Abstract
Tuberculosis (TB), a dreadful disease is one of the most important health problems worldwide, and is responsible for approximately 1.3 million death tolls in 2012. DOTS is the currently used drug therapy in TB and the long term drug regimens and patients’ poor compliance lead to emergence of multidrug resistant (MDR) and extensively drug resistant (XDR) TB, which invigorates the research efforts to address the urgent need for the quick diagnosis and for newer antitubercular agents and vaccines to completely eradicate TB. Today we have at least 20 new diagnostic test platforms, 14 TB vaccine candidates in clinical trials and over 35 candidates in preclinical development, and among the antitubercular agents under clinical investigation, 4 anti-TB agents are in Phase III (efficacy) trials and 7 anti-TB agents are in Phase II, early bactericidal activity and sputum culture conversion trials (rifapentine is in a Phase II and a Phase III trial), 5 anti-TB agents in preclinical development and 3 anti-TB agents in Good Laboratory Practice toxicity evaluation. Recently US FDA has approved TMC207 as a part of combination therapy to treat adults with MDR pulmonary TB in the absence of other alternatives. We provide here the concise review on the chemical entities currently in the clinical trials, the new vaccines in the developmental pipeline, and the new diagnostic test.
Keywords: Antitubercular agents, review, tuberculosis, tubercular vaccines, tuberculosis diagnosis.
Infectious Disorders - Drug Targets
Title:Tuberculosis: Current Treatment, Diagnostics, and Newer Antitubercular Agents in Clinical Trials
Volume: 15 Issue: 1
Author(s): Mohamed Jawed Ahsan, Mohammad Yousuf Ansari, Sabina Yasmin, Surender Singh Jadav, Pradeep Kumar, Shiv Kumar Garg, Ajay Aseri and Habibullah Khalilullah
Affiliation:
Keywords: Antitubercular agents, review, tuberculosis, tubercular vaccines, tuberculosis diagnosis.
Abstract: Tuberculosis (TB), a dreadful disease is one of the most important health problems worldwide, and is responsible for approximately 1.3 million death tolls in 2012. DOTS is the currently used drug therapy in TB and the long term drug regimens and patients’ poor compliance lead to emergence of multidrug resistant (MDR) and extensively drug resistant (XDR) TB, which invigorates the research efforts to address the urgent need for the quick diagnosis and for newer antitubercular agents and vaccines to completely eradicate TB. Today we have at least 20 new diagnostic test platforms, 14 TB vaccine candidates in clinical trials and over 35 candidates in preclinical development, and among the antitubercular agents under clinical investigation, 4 anti-TB agents are in Phase III (efficacy) trials and 7 anti-TB agents are in Phase II, early bactericidal activity and sputum culture conversion trials (rifapentine is in a Phase II and a Phase III trial), 5 anti-TB agents in preclinical development and 3 anti-TB agents in Good Laboratory Practice toxicity evaluation. Recently US FDA has approved TMC207 as a part of combination therapy to treat adults with MDR pulmonary TB in the absence of other alternatives. We provide here the concise review on the chemical entities currently in the clinical trials, the new vaccines in the developmental pipeline, and the new diagnostic test.
Export Options
About this article
Cite this article as:
Jawed Ahsan Mohamed, Yousuf Ansari Mohammad, Yasmin Sabina, Jadav Surender Singh, Kumar Pradeep, Kumar Garg Shiv, Aseri Ajay and Khalilullah Habibullah, Tuberculosis: Current Treatment, Diagnostics, and Newer Antitubercular Agents in Clinical Trials, Infectious Disorders - Drug Targets 2015; 15 (1) . https://dx.doi.org/10.2174/1871526514666140923153329
DOI https://dx.doi.org/10.2174/1871526514666140923153329 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
From Conventional Reaction Conditions to Microwave-Assisted Catalytic Transformations of Various Substrates. State of the Art in 2012 (Part A: General)
Current Organic Chemistry A Universal, Fully Automated High Throughput Screening Assay for Pyrophosphate and Phosphate Release from Enzymatic Reactions
Combinatorial Chemistry & High Throughput Screening Natural Compounds for Overcoming Multidrug Resistance in Mycobacteria
Recent Patents on Biotechnology XDR-TB, What is it; How is it Treated; and why is Therapeutic Failure so High?
Recent Patents on Anti-Infective Drug Discovery In Silico Assessment of Adverse Effects of a Large Set of 6-Fluoroquinolones Obtained from a Study of Tuberculosis Chemotherapy
Current Drug Safety Beneficial Effects of Liposomal Formulations of Lichen Substances: A Review
Current Drug Delivery Ribonucleotide Reductase: A Critical Enzyme for Cancer Chemotherapy and Antiviral Agents
Recent Patents on Anti-Cancer Drug Discovery Therapeutic Outlook of Pyrazole Analogs: A Mini Review
Mini-Reviews in Medicinal Chemistry Operational Issues and Barriers to Implementation of Prevention of Mother-to-Child Transmission of HIV (PMTCT) Interventions in Sub- Saharan Africa
Current HIV Research An Update on the Synthesis and Applications of Bis(Naphthoquinones): An Important Class of Molecules against Infectious Diseases and other Conditions
Current Topics in Medicinal Chemistry Natural Products: Key Prototypes to Drug Discovery Against Neglected Diseases Caused by Trypanosomatids
Current Medicinal Chemistry Cytokines as a Therapeutic Target for Allergic Diseases: A Complex Picture
Current Pharmaceutical Design Subject Index To Volume 2
Current Respiratory Medicine Reviews Editorial (Thematic Issue: Enzymatic Studies in Medicinal Chemistry of Neglected Diseases)
Current Protein & Peptide Science Skeletal Muscle in Cancer Cachexia: The Ideal Target of Drug Therapy
Current Cancer Drug Targets The Physiology of Nitric Oxide: Control and Consequences
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Immunotoxicity and Immunogenicity of Biopharmaceuticals: Design Concepts and Safety Assessment
Current Drug Safety Radical Releasing Anti-tuberculosis Agents and the Treatment of <i>Mycobacterial Tuberculosis</i> Infections - An Overview
Mini-Reviews in Medicinal Chemistry New insights on Ethambutol Targets in Mycobacterium tuberculosis
Infectious Disorders - Drug Targets Inter-Species/Host-Parasite Protein Interaction Predictions Reviewed
Current Bioinformatics